IDH2 and acute myeloid leukemia: It has been suggested that testing AML patients for IDH mutation status is simple and should be performed universally; however, the relationship between IDH mutation status and prognosis is considerably less clear and more controversial in AML than it is in other cancers such as glioma (46, 55).